Valuation: Milestone Pharmaceuticals Inc.

Market Cap 64.88M 59.17M 54.7M 49.37M 92.98M 6.06B 96.64M 661M 261M 3.27B 243M 238M 10.33B P/E 2026 *
-0.58x
P/E 2027 * -0.75x
Enterprise Value 64.88M 59.17M 54.7M 49.37M 92.98M 6.06B 96.64M 661M 261M 3.27B 243M 238M 10.33B EV / Sales 2026 *
13.3x
EV / Sales 2027 * 5.17x
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -
11-13 Milestone Pharmaceuticals Inc., Q3 2026 Earnings Call, Nov 13, 2026
11-13 Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-02 Milestone Pharmaceuticals Inc. Presents New Data On CARDAMYST Nasal Spray Conversion Of Recurrent PSVT To Normal Heart Rhythm In Patients With Prior Catheter Ablation CI
10-09 Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial Fibrillation MT
10-09 Milestone Pharmaceuticals Inc. Enrolls First European Patient In ReVeRA-301 Phase 3 Clinical Trial Evaluating Etripamil Nasal Spray For AFib-RVR CI
09-24 Milestone Pharmaceuticals Enrolls First Canadian Study Participant In ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray For AFib-RVR CI
09-03 Milestone Pharmaceuticals Receives Nmpa Approval for Etripamil Nasal Spray for Psvt in China CI
08-27 Milestone Pharmaceuticals Presents Data On The Impact Of Paroxysmal Supraventricular Tachycardia On Patients? Daily Lives And Quality Of Life Between Episodes At ESC Congress 2026 CI
08-21 Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial Of Etripamil Nasal Spray For Self-Administered Treatment Of Atrial Fibrillation With Rapid Ventricular Rate CI
08-21 Milestone Starts Phase 3 Trial of Nasal Spray for Atrial Fibrillation With Rapid Heart Rate MT
08-20 Cantor Fitzgerald Initiates Milestone Pharmaceuticals at Overweight With $3 Price Target MT
08-12 Milestone Pharmaceuticals Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12 Milestone Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
1 day+11.42%
1 week-30.47%
Current month-36.93%
1 month-34.91%
3 months-56.97%
6 months-68.47%
Current year-77.21%
1 week 0.36
Extreme 0.362
0.7
1 month 0.36
Extreme 0.362
0.84
Current year 0.36
Extreme 0.362
2.34
1 year 0.36
Extreme 0.362
3.06
3 years 0.36
Extreme 0.362
3.52
5 years 0.36
Extreme 0.362
9.85
10 years 0
Extreme 0
27.95
Manager TitleAgeSince
Chief Executive Officer 59 07/03/2017
Director of Finance/CFO 53 09/09/2019
Compliance Officer 48 10/02/2026
Director TitleAgeSince
Director/Board Member 59 01/07/2017
Director/Board Member 60 01/04/2019
Director/Board Member 67 01/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/06/26 Free

Director

77,000 0.0618%
20/04/26 Buy

Chief Executive Officer

16,584 0.0141%
20/04/26 Buy

Chief Executive Officer

11,556 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+11.42%-30.47%-80.90%-79.07% 58.22M
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average +0.28%-7.30%+22.66%+144.03% 40B
Weighted average by Cap. -0.84%-3.65%+34.20%+143.94%

Financials

2026 *2027 *
Net sales 4.88M 4.45M 4.12M 3.72M 7M 456M 7.28M 49.74M 19.66M 246M 18.32M 17.94M 778M 12.55M 11.45M 10.58M 9.55M 17.99M 1.17B 18.7M 128M 50.53M 633M 47.09M 46.1M 2B
Net income -109M -99.69M -92.18M -83.18M -157M -10.21B -163M -1.11B -440M -5.51B -410M -402M -17.41B -87.45M -79.75M -73.74M -66.55M -125M -8.17B -130M -891M -352M -4.41B -328M -321M -13.93B
Net Debt - -
Projected Income Statement - Annual - Milestone Pharmaceuticals Inc.
Logo Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Employees
38
Date Price Change Volume
18/11/26 $0.4604 +11.42% 2,227,971
17/11/26 $0.4132 +13.21% 5,591,048
16/11/26 $0.3650 -29.81% 8,803,345
13/11/26 $0.5200 -20.63% 4,198,826
12/11/26 $0.6552 -1.06% 1,091,756
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Milestone Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.4604USD
Average target price
3.857USD
Spread / Average Target
+737.78%
  1. Stock Market
  2. Stocks
  3. MIST Stock